SCHEMBL5582903

SCHEMBL5582903

CC(C)(C)OC(=O)N1CCCC(Cc2ccc(N)cc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.50
CTSD P07339 1/20 0.50
ACKR3 P25106 1/20 0.48
FEN1 P39748 2/20 0.46
ALOX5AP P20292 1/20 0.46
KDM1A O60341 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
GLS O94925 2/20 0.45
ITGB1 P05556 1/20 0.44
ITGA4 P13612 1/20 0.44
BCHE P06276 2/20 0.44
HTR6 P50406 2/20 0.44
CYP2C9 P11712 1/20 0.44
NR1H2 P55055 1/20 0.44
SCN9A Q15858 1/20 0.43
USP30 Q70CQ3 2/20 0.43
CHEK2 O96017 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23887590 0.93 KDM4E (0.47) FEN1ALOX5APALDH1A1MAPTNR1H2
SCHEMBL29347992 0.89 GPR119 (0.53) BACE1CTSDACKR3FEN1KDM1A
SCHEMBL12695300 0.88 BACE1 (0.51) BACE1CTSDACKR3FEN1ALOX5AP
SCHEMBL4149104 0.88 CCR3 (0.51) ACKR3ALDH1A1KMT2ASCN9A
SCHEMBL21358915 0.88 CCR3 (0.51) ACKR3ALDH1A1KMT2ASCN9A
SCHEMBL22036273 0.88 MEN1 (0.53) BACE1CTSDACKR3FEN1KDM1A
SCHEMBL8237687 0.88 ACKR3 (0.57) ACKR3FEN1KDM1ABCHEHTR6
SCHEMBL6214983 0.88 ACKR3 (0.57) ACKR3FEN1KDM1ABCHEHTR6
SCHEMBL17541961 0.87 JAK3 (0.48) FEN1ALOX5APALDH1A1MAPTNR1H2
SCHEMBL15331285 0.86 BACE1 (0.46) BACE1CTSDACKR3FEN1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-7115750-B1 Melanin concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed
EP-1218336-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2002-07-03 EP disclosed
WO-2001021577-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173498-A1 Melanin concentrating hormone antagonist MC1R, MCHR1, MCHR2 BACE1 4696/4885CTSD 4536/4885ACKR3 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.